Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34)

Marja Hurley, Wei Yao, Nancy E Lane

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Since the ability of parathyroid hormone (PTH) to increase osteoblast maturation and activity is associated with basic fibroblast growth factor (bFGF) we determined the changes in serum bFGF levels in patients treated with human parathyroid hormone (hPTH) (1-34) for 12 months and 12 months follow up. All studied subjects (n = 51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n = 28), or to a control group (n = 23). Osteocalcin (OST), bone-specific alkaline phosphatase (BSAP) and bFGF were monitored at the baseline, every 3 months for 18 months, and at 24 months. In the hPTH group, OST increased by more than 150% above baseline at 3 months and was maintained at this level throughout the treatment period. BSAP had increased more than 80% over the baseline level at 3 months and was maintained at 90% above baseline for the next 9 months. bFGF levels had increased by 45% at 3 months, 60% at 6 to 9 months (P < 0.05) and had increased more than 90% from baseline by 12 months (P < 0.05). We found that daily hPTH injections increased bFGF levels. These results support the hypothesis that up-regulation of bFGF could play a role in the osteoblastic response to PTH.

Original languageEnglish (US)
Pages (from-to)2080-2084
Number of pages5
JournalOsteoporosis International
Volume16
Issue number12
DOIs
StatePublished - Dec 2005

Fingerprint

Teriparatide
Fibroblast Growth Factor 2
Glucocorticoids
Osteoporosis
Serum
Osteocalcin
Parathyroid Hormone
Alkaline Phosphatase
Estrogens
Bone and Bones
Postmenopausal Osteoporosis
Osteoblasts
Progesterone
Up-Regulation
Control Groups
Injections
Therapeutics
human PTH protein

Keywords

  • bFGF
  • Osteoporosis
  • PTH

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{95a86e16153c44bda78a831393a77689,
title = "Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34)",
abstract = "Since the ability of parathyroid hormone (PTH) to increase osteoblast maturation and activity is associated with basic fibroblast growth factor (bFGF) we determined the changes in serum bFGF levels in patients treated with human parathyroid hormone (hPTH) (1-34) for 12 months and 12 months follow up. All studied subjects (n = 51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n = 28), or to a control group (n = 23). Osteocalcin (OST), bone-specific alkaline phosphatase (BSAP) and bFGF were monitored at the baseline, every 3 months for 18 months, and at 24 months. In the hPTH group, OST increased by more than 150{\%} above baseline at 3 months and was maintained at this level throughout the treatment period. BSAP had increased more than 80{\%} over the baseline level at 3 months and was maintained at 90{\%} above baseline for the next 9 months. bFGF levels had increased by 45{\%} at 3 months, 60{\%} at 6 to 9 months (P < 0.05) and had increased more than 90{\%} from baseline by 12 months (P < 0.05). We found that daily hPTH injections increased bFGF levels. These results support the hypothesis that up-regulation of bFGF could play a role in the osteoblastic response to PTH.",
keywords = "bFGF, Osteoporosis, PTH",
author = "Marja Hurley and Wei Yao and Lane, {Nancy E}",
year = "2005",
month = "12",
doi = "10.1007/s00198-005-1998-x",
language = "English (US)",
volume = "16",
pages = "2080--2084",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "12",

}

TY - JOUR

T1 - Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34)

AU - Hurley, Marja

AU - Yao, Wei

AU - Lane, Nancy E

PY - 2005/12

Y1 - 2005/12

N2 - Since the ability of parathyroid hormone (PTH) to increase osteoblast maturation and activity is associated with basic fibroblast growth factor (bFGF) we determined the changes in serum bFGF levels in patients treated with human parathyroid hormone (hPTH) (1-34) for 12 months and 12 months follow up. All studied subjects (n = 51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n = 28), or to a control group (n = 23). Osteocalcin (OST), bone-specific alkaline phosphatase (BSAP) and bFGF were monitored at the baseline, every 3 months for 18 months, and at 24 months. In the hPTH group, OST increased by more than 150% above baseline at 3 months and was maintained at this level throughout the treatment period. BSAP had increased more than 80% over the baseline level at 3 months and was maintained at 90% above baseline for the next 9 months. bFGF levels had increased by 45% at 3 months, 60% at 6 to 9 months (P < 0.05) and had increased more than 90% from baseline by 12 months (P < 0.05). We found that daily hPTH injections increased bFGF levels. These results support the hypothesis that up-regulation of bFGF could play a role in the osteoblastic response to PTH.

AB - Since the ability of parathyroid hormone (PTH) to increase osteoblast maturation and activity is associated with basic fibroblast growth factor (bFGF) we determined the changes in serum bFGF levels in patients treated with human parathyroid hormone (hPTH) (1-34) for 12 months and 12 months follow up. All studied subjects (n = 51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n = 28), or to a control group (n = 23). Osteocalcin (OST), bone-specific alkaline phosphatase (BSAP) and bFGF were monitored at the baseline, every 3 months for 18 months, and at 24 months. In the hPTH group, OST increased by more than 150% above baseline at 3 months and was maintained at this level throughout the treatment period. BSAP had increased more than 80% over the baseline level at 3 months and was maintained at 90% above baseline for the next 9 months. bFGF levels had increased by 45% at 3 months, 60% at 6 to 9 months (P < 0.05) and had increased more than 90% from baseline by 12 months (P < 0.05). We found that daily hPTH injections increased bFGF levels. These results support the hypothesis that up-regulation of bFGF could play a role in the osteoblastic response to PTH.

KW - bFGF

KW - Osteoporosis

KW - PTH

UR - http://www.scopus.com/inward/record.url?scp=29044441653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29044441653&partnerID=8YFLogxK

U2 - 10.1007/s00198-005-1998-x

DO - 10.1007/s00198-005-1998-x

M3 - Article

VL - 16

SP - 2080

EP - 2084

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 12

ER -